諾唯贊(688105.SH):發明專利"一種Taq DNA聚合酶突變體Mut4及其應用"榮獲第二十五屆中國專利優秀獎
格隆匯6月8日丨諾唯贊(688105.SH)公佈,國家知識產權局於近日發佈了《關於第二十五屆中國專利獎授獎的決定》(國知發運字〔2025〕20 號),南京諾唯贊生物科技股份有限公司(以下簡稱"公司")的發明專利"一種 Taq DNA 聚合酶突變體 Mut4 及其應用"榮獲第二十五屆中國專利優秀獎,具體情況如下:
專利名稱:一種 Taq DNA 聚合酶突變體 Mut4 及其應用
專 利 號:ZL202010980814.1
專利權人:南京諾唯贊生物科技股份有限公司
該專利系基於公司蛋白質定向改造與進化核心技術平臺的自主研發成果,可以提高核心產品酶的耐受能力和針對高濃度血液樣本的擴增性能,廣泛應用於高通量測序、食品安全檢測、動物檢驗檢疫、醫療診斷檢測等方面。此次獲獎,是對公司技術創新實力和知識產權工作開展的充分認可,有助於發揮公司自主知識產權優勢,推進公司研發創新成果轉化,提升公司技術創新能力和核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.